Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SCOTT T GUENTHNER

Allopathic & Osteopathic Physicians Dermatology

NPI
1396748778
CMS profile
154244
Location
PLAINFIELD, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$499,541.98

595 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 3 of 12; records 101–150 of 595 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SCOTT T GUENTHNER

NPI 1396748778 · CMS profile ID 154244

Allopathic & Osteopathic Physicians / Dermatology

PLAINFIELD, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 12; records 101–150 of 595 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1396748778?year=2024&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SCOTT T GUENTHNER, NPI 1396748778, CMS profile ID 154244. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 12; records 101–150 of 595 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1396748778?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). SCOTT T GUENTHNER, NPI 1396748778, CMS profile ID 154244. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 12; records 101–150 of 595 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1396748778?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
SCOTT T GUENTHNER, NPI 1396748778, CMS profile ID 154244, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 12; records 101–150 of 595 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1396748778?year=2024&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

595 matching records · $499,541.98 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 595 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 595.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
SUN PHARMACEUTICAL INDUSTRIES INC. $124.9911/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152200591 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $878.4011/06/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152200593 CMS
GENZYME CORPORATION $4.0011/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139687799 CMS
Lilly USA, LLC $14.0011/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135411285 CMS
Novartis Pharmaceuticals Corporation $4.0511/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086833615 CMS
Dermavant Sciences, Inc. $6.1511/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127873603 CMS
Regeneron Healthcare Solutions, Inc. $15.2611/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114061281 CMS
Janssen Biotech, Inc. $38.7311/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078631348 CMS
Janssen Biotech, Inc. $57.9311/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078631531 CMS
Janssen Biotech, Inc. $38.3011/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078631798 CMS
Janssen Biotech, Inc. $375.3011/01/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078631762 CMS
PFIZER INC. $14.1711/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131018285 CMS
Novartis Pharmaceuticals Corporation $6.1610/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086833617 CMS
Arcutis Biotherapeutics, Inc. $10.9110/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1121072747 CMS
GENZYME CORPORATION $56.4910/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139687827 CMS
GENZYME CORPORATION $7,014.0010/29/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139687829 CMS
GENZYME CORPORATION $198.2410/29/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139687831 CMS
GENZYME CORPORATION $1,169.4610/29/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139687833 CMS
GENZYME CORPORATION $26.8010/29/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139687835 CMS
Janssen Biotech, Inc. $7.6410/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078631595 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $19.5010/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153816963 CMS
PFIZER INC. $19.3310/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132078803 CMS
GENZYME CORPORATION $19.4910/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139687797 CMS
Galderma Laboratories, L.P. $6.7610/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145301813 CMS
Galderma Laboratories, L.P. $640.5810/28/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145301815 CMS
Galderma Laboratories, L.P. $110.4710/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145301817 CMS
Janssen Biotech, Inc. $28.4710/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078631492 CMS
Dermavant Sciences, Inc. $7,200.0010/24/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127873588 CMS
Dermavant Sciences, Inc. $4,800.0010/24/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127873592 CMS
Dermavant Sciences, Inc. $3,200.0010/24/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127873596 CMS
Dermavant Sciences, Inc. $3,200.0010/24/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127873600 CMS
Incyte Corporation $40.1010/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141205653 CMS
LEO Pharma Inc. $47.0910/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152632571 CMS
Regeneron Healthcare Solutions, Inc. $46.4710/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114061279 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $22.5010/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153757107 CMS
Arcutis Biotherapeutics, Inc. $37.0010/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1121072749 CMS
Dermavant Sciences, Inc. $30.2910/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127873585 CMS
Galderma Laboratories, L.P. $2,250.0010/23/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145301811 CMS
Incyte Corporation $138.4410/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141205591 CMS
Janssen Research & Development, LLC $962.0010/23/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1077590377 CMS
UCB, Inc. $33.4110/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143015672 CMS
Biofrontera Inc. $18.7210/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1107999964 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $20.3510/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117993702 CMS
Galderma Laboratories, L.P. $113.5210/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145301809 CMS
Incyte Corporation $23.1210/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141313071 CMS
ABBVIE INC. $3,500.0010/17/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103152816 CMS
ABBVIE INC. $3,500.0010/17/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103152818 CMS
ABBVIE INC. $4,900.0010/17/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103152820 CMS
Dermavant Sciences, Inc. $115.0010/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127873570 CMS
Dermavant Sciences, Inc. $716.9410/16/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127873574 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $80,014.30 311
PY2020 $36,706.82 154
PY2021 $57,960.84 183
PY2022 $148,122.80 264
PY2023 $324,395.49 381
PY2024 $499,541.98 595
PY2025 $493,979.43 540

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,201,070.78 147
PY2024 Recipient $104.58 1
PY2024 Principal investigator $1,501,958.86 619
PY2023 Recipient $5,500.00 1
PY2023 Principal investigator $1,258,025.01 629
PY2022 Recipient $3,236.49 3
PY2022 Principal investigator $990,155.85 312
PY2021 Recipient $26,862.89 2
PY2021 Principal investigator $1,423,829.74 155
PY2020 Recipient $19,508.34 16
PY2020 Principal investigator $1,057,824.31 213
PY2019 Recipient $72,878.15 31
PY2019 Principal investigator $1,578,189.19 248

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

147 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 SANOFI US SERVICES INC. $485.00 12/24/2025 Non-covered Recipient Entity
The Indiana Clinical Trials Center
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226105802
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $600.00 12/24/2025 Non-covered Recipient Entity
The Indiana Clincal Trials Center
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246435235
Principal investigator 1 Janssen Research & Development, LLC $4,226.00 12/22/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTER
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surface Area No dispute reported 06/30/2026 1175333614
Principal investigator 1 Incyte Corporation $3,148.00 12/19/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTRE, PC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240602165
Principal investigator 1 Incyte Corporation $2,027.00 12/19/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTRE, PC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240602174
Principal investigator 1 Incyte Corporation $1,890.00 12/19/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTRE, PC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240602193
Principal investigator 1 Incyte Corporation $2,131.00 12/19/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTRE, PC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240602212
Principal investigator 1 Janssen Research & Development, LLC $2,558.00 12/19/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTER
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175333885
Principal investigator 1 Incyte Corporation $40.00 12/18/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTRE, PC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240602182
Principal investigator 1 Incyte Corporation $544.00 12/18/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTRE, PC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240602189
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $7,078.26 12/18/2025 Non-covered Recipient Entity
The Indiana Clincal Trials Center
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246435145
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $3,246.75 12/12/2025 Non-covered Recipient Entity
The Indiana Clincal Trials Center
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246435232
Principal investigator 1 Janssen Research & Development, LLC $300.00 12/11/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTER
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175333803
Principal investigator 1 ABBVIE INC. $9,200.00 12/10/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CTR PC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202529924
Principal investigator 1 Janssen Research & Development, LLC $420.00 12/08/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTER
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surface Area No dispute reported 06/30/2026 1175333713
Principal investigator 1 Biofrontera Inc. $4,759.13 12/05/2025 Non-covered Recipient Entity
INDIANA CLINICAL TRIALS CENTER
STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP No dispute reported 06/30/2026 1208907785
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,324.25 12/04/2025 Non-covered Recipient Entity
The Indiana Clincal Trials Center
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246435213
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $5,801.90 12/04/2025 Non-covered Recipient Entity
The Indiana Clincal Trials Center
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246435217
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $7,088.47 12/04/2025 Non-covered Recipient Entity
The Indiana Clincal Trials Center
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246435221
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $10,231.65 12/04/2025 Non-covered Recipient Entity
The Indiana Clincal Trials Center
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246435225
Principal investigator 1 Incyte Corporation $7,500.00 12/01/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTRE, PC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240602170
Principal investigator 1 Janssen Research & Development, LLC $4,970.00 12/01/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTER
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1175333770
Principal investigator 1 Biofrontera Inc. $16,701.00 11/28/2025 Non-covered Recipient Entity
INDIANA CLINICAL TRIALS CENTER
STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP No dispute reported 06/30/2026 1208907764
Principal investigator 1 Biofrontera Inc. $341.14 11/28/2025 Non-covered Recipient Entity
INDIANA CLINICAL TRIALS CENTER
STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP No dispute reported 06/30/2026 1208907769
Principal investigator 1 Biofrontera Inc. $47,343.61 11/28/2025 Non-covered Recipient Entity
INDIANA CLINICAL TRIALS CENTER
OPEN-LABEL PHASE I STUDY TO EVALUATE THE PHARMACOKINETICS OF 5-AMINOLEVULINIC ACID AND PROTOPORPHYRIN IX IN HUMAN PLASMA UNDER MAXIMAL USE CONDITIONS AFTER TOPICAL APPLICATION OF 3 TUBES OF BF-200 ALA TO A TREATMENT FIELD OF 240 CM2 FOR PHOTODYNAMIC THERAPY (PDT) IN SUBJECTS SUFFERING FROM ACTINIC KERATOSIS IN THE PERIPHERY No dispute reported 06/30/2026 1208907772
Principal investigator 1 Biofrontera Inc. $1,173.00 11/28/2025 Non-covered Recipient Entity
INDIANA CLINICAL TRIALS CENTER
OPEN-LABEL PHASE I STUDY TO EVALUATE THE PHARMACOKINETICS OF 5-AMINOLEVULINIC ACID AND PROTOPORPHYRIN IX IN HUMAN PLASMA UNDER MAXIMAL USE CONDITIONS AFTER TOPICAL APPLICATION OF 3 TUBES OF BF-200 ALA TO A TREATMENT FIELD OF 240 CM2 FOR PHOTODYNAMIC THERAPY (PDT) IN SUBJECTS SUFFERING FROM ACTINIC KERATOSIS IN THE PERIPHERY No dispute reported 06/30/2026 1208907776
Principal investigator 1 Incyte Corporation $1,834.00 11/21/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTRE, PC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240602196
Principal investigator 1 Incyte Corporation $2,500.00 11/14/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTRE, PC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240602167
Principal investigator 1 Incyte Corporation $500.00 11/14/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTRE, PC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240602178
Principal investigator 1 Incyte Corporation $1,200.00 11/14/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTRE, PC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240602201
Principal investigator 1 Incyte Corporation $8,500.00 11/14/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTRE, PC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240602216
Principal investigator 1 Janssen Research & Development, LLC $215.00 11/14/2025 Non-covered Recipient Entity
The Indiana Clinic Trials Ctr
A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics No dispute reported 06/30/2026 1175219400
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $7,631.54 11/13/2025 Non-covered Recipient Entity
The Indiana Clincal Trials Center
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246435138
Principal investigator 1 Janssen Research & Development, LLC $212.00 11/10/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTER
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1175333699
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 11/10/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTER
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1175333782
Principal investigator 1 Janssen Research & Development, LLC $11,200.00 11/10/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTER
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1175333837
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $9,434.88 11/05/2025 Non-covered Recipient Entity
The Indiana Clincal Trials Center
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246435208
Principal investigator 1 Vanda Pharmaceuticals Inc. $5,400.00 11/05/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTER
Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness No dispute reported 06/30/2026 1232946825
Principal investigator 1 Incyte Corporation $1,000.00 11/03/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTRE, PC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240602161
Principal investigator 1 Incyte Corporation $1,500.00 11/03/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTRE, PC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240602222
Principal investigator 1 Janssen Research & Development, LLC $2,558.00 10/31/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTER
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175333524
Principal investigator 1 Janssen Research & Development, LLC $5,605.00 10/31/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTER
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surface Area No dispute reported 06/30/2026 1175333570
Principal investigator 1 Janssen Research & Development, LLC $2,226.00 10/23/2025 Non-covered Recipient Entity
The Indiana Clinic Trials Ctr
A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics No dispute reported 06/30/2026 1175219379
Principal investigator 1 Janssen Research & Development, LLC $311.00 10/23/2025 Non-covered Recipient Entity
The Indiana Clinic Trials Ctr
A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics No dispute reported 06/30/2026 1175219409
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $11,806.42 10/23/2025 Non-covered Recipient Entity
The Indiana Clincal Trials Center
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246435122
Principal investigator 1 Incyte Corporation $2,131.00 10/22/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTRE, PC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240602157
Principal investigator 1 Incyte Corporation $3,148.00 10/22/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTRE, PC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240602185
Principal investigator 1 Vanda Pharmaceuticals Inc. $200.00 10/22/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTER
Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness No dispute reported 06/30/2026 1232946610
Principal investigator 1 Vanda Pharmaceuticals Inc. $2,350.00 10/22/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTER
Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness No dispute reported 06/30/2026 1232946614
Principal investigator 1 Eli Lilly and Company $15,344.00 10/14/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTER PC
A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1187891212
Principal investigator 1 Incyte Corporation $544.00 10/13/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTRE, PC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240602205
Principal investigator 1 Incyte Corporation $10.00 10/13/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTRE, PC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240602209
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $2,404.35 10/10/2025 Non-covered Recipient Entity
The Indiana Clincal Trials Center
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246435205
Principal investigator 1 Janssen Research & Development, LLC $100.00 10/09/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTER
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175333867
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $5,712.35 10/09/2025 Non-covered Recipient Entity
The Indiana Clincal Trials Center
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246435112
Principal investigator 1 Janssen Research & Development, LLC $3,302.00 09/29/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTER PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175333563
Principal investigator 1 Janssen Research & Development, LLC $2,710.00 09/29/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTER PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1175333992
Principal investigator 1 Janssen Research & Development, LLC $2,316.00 09/29/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTER PC
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1175334158
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $9,634.95 09/25/2025 Non-covered Recipient Entity
The Indiana Clincal Trials Center
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246435201
Principal investigator 1 Janssen Research & Development, LLC $1,532.00 09/08/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTER PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175333674
Principal investigator 1 Janssen Research & Development, LLC $2,710.00 09/08/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTER PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1175333743
Principal investigator 1 Janssen Research & Development, LLC $6,500.00 09/08/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTER PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175334060
Principal investigator 1 Janssen Research & Development, LLC $1,651.00 09/04/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTER PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175334110
Principal investigator 1 Biofrontera Inc. $18,579.44 08/22/2025 Non-covered Recipient Entity
INDIANA CLINICAL TRIALS CENTER
STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP No dispute reported 06/30/2026 1208907588
Principal investigator 1 Biofrontera Inc. $16,743.23 08/22/2025 Non-covered Recipient Entity
INDIANA CLINICAL TRIALS CENTER
STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP No dispute reported 06/30/2026 1208907604
Principal investigator 1 Biofrontera Inc. $5,000.00 08/22/2025 Non-covered Recipient Entity
INDIANA CLINICAL TRIALS CENTER
STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP No dispute reported 06/30/2026 1208907607
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $2,164.50 08/20/2025 Non-covered Recipient Entity
The Indiana Clincal Trials Center
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246435197
Principal investigator 1 Janssen Research & Development, LLC $4,308.00 08/18/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTER PC
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1175333879
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $5,258.82 08/13/2025 Non-covered Recipient Entity
The Indiana Clincal Trials Center
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246435104
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $23,341.53 08/12/2025 Non-covered Recipient Entity
The Indiana Clincal Trials Center
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246435092
Principal investigator 1 Janssen Research & Development, LLC $6,824.00 08/08/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTER PC
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1175334070
Principal investigator 1 ABBVIE INC. $4,000.00 08/05/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CTR PC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202501816
Principal investigator 1 Janssen Research & Development, LLC $2,113.00 08/04/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTER PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1175333540
Principal investigator 1 Janssen Research & Development, LLC $2,988.00 08/01/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTER PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175333998
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $8,650.00 08/01/2025 Non-covered Recipient Entity
The Indiana Clincal Trials Center
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246435192
Principal investigator 1 ABBVIE INC. $50,756.69 07/31/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CTR PC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202500746
Principal investigator 1 Janssen Research & Development, LLC $1,484.00 07/31/2025 Non-covered Recipient Entity
The Indiana Clinic Trials Ctr
A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics No dispute reported 06/30/2026 1175219372
Principal investigator 1 Vanda Pharmaceuticals Inc. $1,300.00 07/16/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTER
Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness No dispute reported 06/30/2026 1232945823
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $8,745.75 07/15/2025 Non-covered Recipient Entity
The Indiana Clincal Trials Center
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246435189
Principal investigator 1 Janssen Research & Development, LLC $4,428.00 07/10/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTER PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1175333622
Principal investigator 1 Biofrontera Inc. $77.28 07/07/2025 Non-covered Recipient Entity
INDIANA CLINICAL TRIALS CENTER
OPEN-LABEL PHASE I STUDY TO EVALUATE THE PHARMACOKINETICS OF 5-AMINOLEVULINIC ACID AND PROTOPORPHYRIN IX IN HUMAN PLASMA UNDER MAXIMAL USE CONDITIONS AFTER TOPICAL APPLICATION OF 3 TUBES OF BF-200 ALA TO A TREATMENT FIELD OF 240 CM2 FOR PHOTODYNAMIC THERAPY (PDT) IN SUBJECTS SUFFERING FROM ACTINIC KERATOSIS IN THE PERIPHERY No dispute reported 06/30/2026 1208907541
Principal investigator 1 Janssen Research & Development, LLC $200.00 07/07/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTER PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175333546
Principal investigator 1 Vanda Pharmaceuticals Inc. $100.00 07/03/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTER
Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness No dispute reported 06/30/2026 1232945660
Principal investigator 1 ABBVIE INC. $11,642.00 07/02/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CTR PC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202495083
Principal investigator 1 Janssen Research & Development, LLC $2,988.00 06/27/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTER PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175333952
Principal investigator 1 Janssen Research & Development, LLC $300.00 06/27/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTER PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175334117
Principal investigator 1 Amgen Inc. $4,100.00 06/26/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTER, PC
A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) No dispute reported 06/30/2026 1246649490
Principal investigator 1 Vanda Pharmaceuticals Inc. $6,700.00 06/25/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTER
Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness No dispute reported 06/30/2026 1232945583
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $4,500.00 06/24/2025 Non-covered Recipient Entity
The Indiana Clincal Trials Center
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246435185
Principal investigator 1 Janssen Research & Development, LLC $5,000.00 06/23/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTER PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175333730
Principal investigator 1 Janssen Research & Development, LLC $1,969.50 06/23/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTER PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1175333735
Principal investigator 1 Janssen Research & Development, LLC $300.00 06/23/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTER PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1175334007
Principal investigator 1 Janssen Research & Development, LLC $12,500.00 06/23/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTER PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175334127
Principal investigator 1 Janssen Research & Development, LLC $96.00 06/19/2025 Non-covered Recipient Entity
The Indiana Clinic Trials Ctr
A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics No dispute reported 06/30/2026 1175219356
Principal investigator 1 Janssen Research & Development, LLC $96.00 06/19/2025 Non-covered Recipient Entity
The Indiana Clinic Trials Ctr
A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics No dispute reported 06/30/2026 1175219367
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $5,902.65 06/17/2025 Non-covered Recipient Entity
The Indiana Clincal Trials Center
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246435182
Principal investigator 1 Janssen Research & Development, LLC $1,484.00 06/12/2025 Non-covered Recipient Entity
The Indiana Clinic Trials Ctr
A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics No dispute reported 06/30/2026 1175219350
Principal investigator 1 Janssen Research & Development, LLC $2,113.00 06/09/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTER PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1175333757
Principal investigator 1 ABBVIE INC. $1,963.60 06/03/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CTR PC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202489845
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $6,201.00 05/27/2025 Non-covered Recipient Entity
The Indiana Clincal Trials Center
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246435177
Principal investigator 1 Janssen Research & Development, LLC $2,988.00 05/22/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTER PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175334086
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,500.00 05/22/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTER
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184198411
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $812.00 05/21/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTER
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184197445
Principal investigator 1 Janssen Research & Development, LLC $9,685.00 05/09/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTER PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1175333749
Principal investigator 1 Eli Lilly and Company $12,580.00 04/28/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTER PC
A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEKIZUMAB IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT IN CLINICAL PRACTICE No dispute reported 06/30/2026 1187890924
Principal investigator 1 Janssen Research & Development, LLC $5,621.00 04/28/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTER PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175334053
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,200.00 04/24/2025 Non-covered Recipient Entity
The Indiana Clincal Trials Center
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246435082
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $9,000.00 04/24/2025 Non-covered Recipient Entity
The Indiana Clincal Trials Center
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246435086
Principal investigator 1 Vanda Pharmaceuticals Inc. $2,700.00 04/23/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTER
Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness No dispute reported 06/30/2026 1232945258
Principal investigator 1 Vanda Pharmaceuticals Inc. $400.00 04/23/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTER
Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness No dispute reported 06/30/2026 1232945262
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $6,581.25 04/11/2025 Non-covered Recipient Entity
The Indiana Clincal Trials Center
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246435173
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $23,524.00 04/09/2025 Non-covered Recipient Entity
The Indiana Clinical Trials Center
A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis No dispute reported 06/30/2026 1235993131
Principal investigator 1 ABBVIE INC. $616.85 04/03/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CTR PC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202472315
Principal investigator 1 Biofrontera Inc. $37,948.61 04/03/2025 Non-covered Recipient Entity
INDIANA CLINICAL TRIALS CENTER
STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP No dispute reported 06/30/2026 1208907433
Principal investigator 1 Janssen Research & Development, LLC $512.00 03/31/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTER PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1175333960
Principal investigator 1 Janssen Research & Development, LLC $5,621.00 03/24/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTER PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175333691
Principal investigator 1 Janssen Research & Development, LLC $384.00 03/20/2025 Non-covered Recipient Entity
The Indiana Clinic Trials Ctr
A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics No dispute reported 06/30/2026 1175219394
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $4,223.70 03/19/2025 Non-covered Recipient Entity
The Indiana Clincal Trials Center
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246435169
Principal investigator 1 ABBVIE INC. $2,879.43 03/07/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CTR PC
M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202461259
Principal investigator 1 Janssen Research & Development, LLC $6,322.00 03/06/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTER PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1175333796
Principal investigator 1 Biofrontera Inc. $12.61 03/04/2025 Non-covered Recipient Entity
INDIANA CLINICAL TRIALS CENTER
STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP No dispute reported 06/30/2026 1208907375
Principal investigator 1 Janssen Research & Development, LLC $3,828.00 03/03/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTER PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175333828
Principal investigator 1 Janssen Research & Development, LLC $2,226.00 03/03/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTER PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175333920
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $5,499.00 03/03/2025 Non-covered Recipient Entity
The Indiana Clincal Trials Center
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246435164
Principal investigator 1 Vanda Pharmaceuticals Inc. $2,600.00 02/25/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTER
Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness No dispute reported 06/30/2026 1232944906
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 02/20/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTER
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184155062
Principal investigator 1 Arcutis Biotherapeutics, Inc. $5,400.00 02/14/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTER PC
A Phase 1b, Randomized, Vehicle-Controlled, Double-Blind, Pharmacokinetics, Pharmacodynamics, and Safety Study of ARQ-255 Topical Suspension in Healthy Volunteers and Subjects with Alopecia Areata No dispute reported 06/30/2026 1248163816
Principal investigator 1 Biofrontera Inc. $17,611.53 02/14/2025 Non-covered Recipient Entity
INDIANA CLINICAL TRIALS CENTER
STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP No dispute reported 06/30/2026 1208907322
Principal investigator 1 Biofrontera Inc. $14,322.71 02/14/2025 Non-covered Recipient Entity
INDIANA CLINICAL TRIALS CENTER
STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP No dispute reported 06/30/2026 1208907327
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $3,747.89 02/14/2025 Non-covered Recipient Entity
The Indiana Clinical Trials Center
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis (POETYK PSO-LTE) No dispute reported 06/30/2026 1235993133
Principal investigator 1 Biofrontera Inc. $37.20 02/13/2025 Non-covered Recipient Entity
INDIANA CLINICAL TRIALS CENTER
STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP No dispute reported 06/30/2026 1208907286
Principal investigator 1 Janssen Research & Development, LLC $2,226.00 02/07/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTER PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175333895
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $6,388.20 02/07/2025 Non-covered Recipient Entity
The Indiana Clincal Trials Center
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246435159
Principal investigator 1 ABBVIE INC. $2,580.45 02/06/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CTR PC
M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202447517
Principal investigator 1 Janssen Research & Development, LLC $11,195.00 01/31/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTER PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1175333722
Principal investigator 1 Arcutis Biotherapeutics, Inc. $1,950.00 01/28/2025 Non-covered Recipient Entity
THE INDIANA CLINIICAL TRIALS -R-SVIP
A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1248163820
Principal investigator 1 Eli Lilly and Company $231,273.00 01/28/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTER PC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187890922
Principal investigator 1 Janssen Research & Development, LLC $778.00 01/23/2025 Non-covered Recipient Entity
The Indiana Clinic Trials Ctr
A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics No dispute reported 06/30/2026 1175219387
Principal investigator 1 Vanda Pharmaceuticals Inc. $1,300.00 01/22/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTER
Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness No dispute reported 06/30/2026 1232944618
Principal investigator 1 Vanda Pharmaceuticals Inc. $1,300.00 01/22/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTER
Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness No dispute reported 06/30/2026 1232944622
Principal investigator 1 Amgen Inc. $57,652.32 01/21/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTER, PC
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) No dispute reported 06/30/2026 1246649501
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $3,733.87 01/17/2025 Non-covered Recipient Entity
The Indiana Clincal Trials Center
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246435153
Principal investigator 1 Eli Lilly and Company $6,266.23 01/15/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTER PC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187892820
Principal investigator 1 Amgen Inc. $110,737.49 01/06/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTER, PC
A Phase 3, 52-Week, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab in Adult Subjects With Prurigo Nodularis Who Are Inadequately Controlled on Topical Therapies or Not Eligible for Topical Therapies No dispute reported 06/30/2026 1246649494
Principal investigator 1 Arcutis Biotherapeutics, Inc. $1,649.50 01/03/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTER PC
A Phase 1b, Randomized, Vehicle-Controlled, Double-Blind, Pharmacokinetics, Pharmacodynamics, and Safety Study of ARQ-255 Topical Suspension in Healthy Volunteers and Subjects with Alopecia Areata No dispute reported 06/30/2026 1248163818
Principal investigator 1 UCB SA $48,698.10 01/03/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CENTER PC
A Phase 3, open-label, parallel group, multicenter, extension study evaluating the long-term treatment of bimekizumab in study participants with moderate to severe hidradenitis suppurativa No dispute reported 06/30/2026 1246657320
Principal investigator 1 ABBVIE INC. $2,580.45 01/02/2025 Non-covered Recipient Entity
THE INDIANA CLINICAL TRIALS CTR PC
M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202434080